Aim Immunotech INC DEF 14A proxy statements

AIM ImmunoTech is seeking shareholder approval for multiple warrant issuances and a potential reverse stock split to maintain NYSE American listing compliance.

AIM ImmunoTech Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 16, 2025, focusing on director elections, auditor ratification, and executive compensation votes.

AIM ImmunoTech is asking stockholders to approve a reverse stock split of up to 1-for-100 to increase its stock price, maintain its NYSE American listing, and improve marketability.

AIM ImmunoTech has distributed additional materials to stockholders regarding the 2024 Annual Meeting, emphasizing the importance of reviewing the definitive proxy statement and related documents.

AIM ImmunoTech is urging shareholders to vote for the current board members at the upcoming annual meeting, warning against the potential risks posed by an activist investor group.

AIM ImmunoTech is urging shareholders to vote for the current board members, highlighting concerns about an activist group's motives and lack of a clear plan.

AIM ImmunoTech is urging shareholders to vote for its incumbent board members after receiving recommendations from proxy advisory firms against activist group nominees.

AIM ImmunoTech has filed proxy materials for its 2024 Annual Meeting and shared an investor presentation.

AIM ImmunoTech has released proxy materials for its 2024 Annual Meeting of Stockholders, urging shareholders to review the documents carefully.

Independent proxy advisory firm ISS recommends shareholders vote for two of AIM ImmunoTech's incumbent board members, while raising concerns about the activist group's nominees and their lack of transparency.

AIM ImmunoTech has released proxy materials for its 2024 Annual Meeting, urging shareholders to review the documents carefully.

AIM ImmunoTech is actively campaigning against the election of activist investor nominees to its board, highlighting their past issues and potential conflicts of interest.

AIM ImmunoTech has released a proxy statement for its 2024 Annual Meeting of Stockholders and included forward-looking statements regarding its research and development.

AIM ImmunoTech announces a cash conservation plan where independent directors will receive 100% of their compensation in stock, aligning with previous executive pay reductions.

AIM ImmunoTech is actively campaigning for the re-election of its current board, highlighting clinical progress and warning against the activist group's self-interested agenda.

AIM ImmunoTech has released an investor presentation to Institutional Shareholder Services Inc. and its stockholders in preparation for the 2024 Annual Meeting.

AIM ImmunoTech is urging shareholders to reject an activist group's attempt to take control of the board at the upcoming 2024 Annual Meeting, citing concerns about the group's motives and potential impact on the company's cash reserves.

AIM ImmunoTech has filed its definitive proxy statement and WHITE universal proxy card with the SEC for its annual meeting.

The Kellner Group, holding approximately 5.04% of AIM ImmunoTech's shares, is soliciting proxies to elect its four nominees to the board, citing significant concerns over the company's performance and governance.

AIM ImmunoTech files its definitive proxy statement, warning shareholders that an activist group's self-interested agenda could disrupt the company's momentum and hinder value creation.

AIM ImmunoTech urges stockholders to vote for its director candidates on the WHITE universal proxy card amidst a proxy solicitation by a dissident group.